You are here: Industry Insights > KN046

News List

Enrollment Completed in Phase II Clinical Study of KN026 Combined with KN046 prnasia
January 13, 2022
Alphamab Oncology (stock code: 9966.HK) announced that the phase II clinical study of KN026 (HER2 bispecific antibody) combined with KN046 (PD-L1/CTLA-4 bispecific antibody) (KN026-203)...
Alphamab Oncology Announced First Patient Dosed in the U.S. in A Phase II Pivotal Clinical Study of KN046 prnasia
December 23, 2021
Alphamab Oncology (stock code: 9966 HK) announced dosing of the first patient of its proprietary PD-L1/CTLA-4 bispecific antibody KN046 in the United States.
Posters Highlighting clinical data of KN026 presented at SABCS 2021 prnasia
December 10, 2021
lphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK) jointly announced that two posters highlighting data from two clinical studies of the anti-HER2 bispecific antibody...
IND Application for Phase 3 Registration Study of KN046 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer was Approved by CDE prnasia
November 24, 2021
Alphamab Oncology (stock code: 9966.HK) announced that the IND application for phase 3 registration study (KN046-303) of the PD-L1/CTLA-4 bispecific antibody KN046 plus nab-paclitaxel/gemcitabine...
Kintor Pharma Doses First Patient in Clinical Trial of ALK-1 in Combination with KN046 In Advanced or Refractory Solid Tumors prnasia
November 03, 2021
Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that the company...
Alphamab Oncology Announces First Patient Dosed in the Pivotal Clinical Study of KN046 for the Treatment of PD-(L)1 Refractory Advanced NSCLC prnasia
October 29, 2021
Alphamab Oncology (stock code: 9966.HK) announced, a pivotal clinical study of PD-L1/CTLA-4 bispecific antibody KN046 in China (ENREACH-LUNG-02) recently completed the first drug administration.
Alphamab Oncology Completed Enrollment in the First Pivotal Phase III Clinical Study of the Bispecific Antibody KN046 prnasia
October 18, 2021
Alphamab Oncology (stock code: 9966.HK), announced that the first phase III pivotal clinical study of PD-L1/CTLA-4 bispecific antibody KN046 in China (ENREACH-LUNG-01) has successfully completed enrollment of all patients.
Poster Highlighting Clinical Data of KN046 Plus Nab-Paclitaxel/Gemcitabine as First-Line Treatment for Pancreatic Cancer Is Presented at ASCO 2021 prnasia
June 07, 2021
Alphamab Oncology announced that data from a Phase II study (KN046-IST-04) of KN046 plus nab-paclitaxel/gemcitabine as first-line treatment for pancreatic ductal adenocarcinoma (PDAC) was presented in a poster session at the ASCO 2021.
Alphamab Oncology Presents Phase 2 Clinical Data on KN046 Combined with Chemotherapy for the Treatment of Advanced NSCLC at ASCO 2021 prnasia
June 07, 2021
Alphamab Oncology announced that data from the Phase II clinical study of the PD-L1/CTLA-4 bispecific antibody KN046 combined with platinum doublet chemotherapy for the treatment of patients with advanced non-small cell lung cancer (NSCLC) is ...
Alphamab Oncology Presents Phase 2 Clinical Data on KN046 Plus Paclitaxel/Cisplatin for the First-line Treatment of ESCC at ASCO 2021 prnasia
June 07, 2021
Alphamab Oncology announced data from Phase 2 clinical study (KN046-204) of KN046(PD-L1/CTLA-4 bispecific antibody) plus paclitaxel/cisplatin for the first-line treatment of unresectable locally advanced, recurrent or metastatic esophageal squamous ...

Previous page 1 2 Next page